Clinical trials: Human Brain and Cognition
Cognitive Change
Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
An open-label, multi-site, validity and reliability study to obtain data on the Cognivue 5-Minute Screening and Cognivue 10-Minute Assessment tests to assess scoring and normative ranges and compare against other cognitive tests…
- Trial name
- FOCUS (NCT05712005)
- Where
- United States
- Volunteers
- 1,437 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Chorea, Huntington
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Trial name
- NCT04400331
- Testing
- Valbenazine
- Where
- 34 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Neurocrine Biosciences
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better.
- Trial name
- NCT00876863
- Testing
- CERE-110: Adeno-Associated Virus injection Surgery
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sangamo Therapeutics
Alzheimer Disease, Huntington Disease
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and…
- Trial name
- NCT00831506
- Testing
- digoxin, dimebon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimers Disease
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 1 (NCT07169578)
- Testing
- Trontinemab
- Where
- 142 sites in United States, Argentina and 11 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Alzheimer Disease
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe.
- Trial name
- NCT00380302
- Testing
- AVE1625
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 162 people
- Sponsor
- Sanofi
Mild Cognitive Impairment (MCI), Parkinson Disease (PD)
A Study of CST-2032 in Subjects With Cognitive Impairment
This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
- Trial name
- NCT05033912
- Sponsor
- CuraSen Therapeutics, Inc.
Huntington Disease
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia.
- Trial name
- Reach2HD (NCT01590888)
- Testing
- PBT2
- Where
- 19 sites in United States, Australia
- Volunteers
- 109 people
- Sponsor
- Prana Biotechnology Limited
Huntington Disease
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD.
- Trial name
- FALCON-HD (NCT07378644)
- Testing
- SKY-0515
- Where
- 31 sites in United States, Argentina and 8 more
- Volunteers
- 400 people
- Sponsor
- Skyhawk Therapeutics, Inc.
Alzheimer's Disease
SB-742457 And Donepezil In Alzheimer's Disease
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease.
- Trial name
- NCT00348192
- Testing
- SB-742457, donepezil
- Where
- 26 sites in Austria, Bulgaria and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Mild Cognitive Impairment
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
- Trial name
- CONCORDE (NCT03448445)
- Testing
- Usual care setting
- Where
- 16 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Eisai Korea Inc.
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Cognitive Disorders
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study drug gets into the brain.
- Trial name
- NCT00937846
- Testing
- GSK1034702
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Huntington's Disease
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease
Deep Brain Stimulation (DBS) of the Globus pallidus internus(GPi) is useful in the treatment of different forms of chorea, including Huntington's disease (HD).
- Trial name
- NCT02263430
- Testing
- Deep Brain Stimulation
- Volunteers
- 8 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Brain Injuries, Growth Hormone Deficiency
Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury
To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.
- Trial name
- NCT00555009
- Testing
- Genotropin
- Where
- 9 sites in France, Italy and 4 more
- Volunteers
- 10 people
- Sponsor
- Pfizer